David M. Feldser, Ph.D.

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Telomeres and telomerase in chromosome maintenance and stability
Google:
"David Feldser"

Parents

Sign in to add mentor
Carol W. Greider grad student 2007 Johns Hopkins
 (Short telomeres: Consequences and mechanisms.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Pierce SE, Granja JM, Corces MR, et al. (2021) LKB1 inactivation modulates chromatin accessibility to drive metastatic progression. Nature Cell Biology
Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, et al. (2021) Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America. 118
Garg R, Cooke M, Benavides F, et al. (2020) PKC epsilon is required for KRAS-driven lung tumorigenesis. Cancer Research
Lin JH, Huffman AP, Wattenberg MM, et al. (2020) Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. The Journal of Experimental Medicine. 217
Tsang T, Posimo JM, Gudiel AA, et al. (2020) Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nature Cell Biology
Kharbanda A, Walter DM, Gudiel AA, et al. (2020) Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis. Science Signaling. 13
Walter DM, Yates TJ, Ruiz-Torres M, et al. (2019) RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature
Stokes KL, Cortez-Retamozo V, Acosta J, et al. (2019) Natural killer cells limit the clearance of senescent lung adenocarcinoma cells. Oncogenesis. 8: 24
Murphy M, Feldser D. (2019) Decision letter: Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase Elife
Acosta J, Wang W, Feldser DM. (2018) Off and back-on again: a tumor suppressor's tale. Oncogene
See more...